Taking people in BelgiumPhase 1
Testing ABO21009 safety in healthy people and rheumatoid arthritis patients
Tests ABO21009, a new medicine, in adults with rheumatoid arthritis and healthy volunteers.
Key facts
- Who runs it
- Aboleris Holdco
- Where
- Edegem and Liège, BelgiumSee the 2 sitesAlso in 2 other countries, 3 sites
- Trial code
- Registry title
- A placebo-controlled, single-blind, phase I study in healthy volunteers and patients with Rheumatoid Arthritis with ABO21009
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 78 people, planned
- Started
- 31 Jan 2025
- Expected to end
- 30 Sept 2027
- Type of study
- Interventional
- Record updated
- 15 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy volunteers and people with rheumatoid arthritis to test ABO21009 against a placebo.
- Age
- 18 years or older
- Sex
- All sexes can join
Where in Belgium
Also in 2 other countries, 3 sites
- SGS BelgiumEdegem, BelgiumTaking people
- Centre Hospitalier Universitaire de LiègeLiège, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Testing ABO21009 safety in healthy people and rheumatoid arthritis patientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 15 June 2026